Dr. Mark Erlander, CEO of Cardiff Oncology discusses their lead drug candidate Onvansertib and the three active clinical trials in colorectal cancer, acute myeloid leukemia, and prostate cancer.  Onvansertib specifically targets and inhibits a downstream enzyme, PLK1, effectively stopping cancer cell division […]